ny-eso-1, magea4, prame, survivin and ssx - specific t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01333046)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ny-eso-1, magea4, prame, survivin and ssx - specific t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01333046 | Phase 1 | Jan 1, 2012 | Baylor University, Methodist Cancer Center, Houston, Texas, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2012 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2012 |
3 organizations
Page 1 / 1